ASCO 2020: Factors influencing outcomes in kidney cancer treated with immunotherapy

A study presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program has identified several features of kidney cancer tumours that influence their response to immune checkpoint inhibitors, such as nivolumab and pembrolizumab. The research was conducted at the Dana-Farber Cancer Institute in America and is published in the journal, Nature Medicine. […]

read more

Research suggests that B cells also play a role in the response to immunotherapy

A recent paper published in the journal Nature earlier this year shed some light on why some patients with soft-tissue sarcoma survived longer than others. The researchers expected that it came down to which patients had the most T cells, an immune cell known to contribute to the success of immunotherapy. However, after studying the […]

read more

Fat near kidney tumours plays a critical role in treatment response

It is already known that obesity increases the risk of developing kidney cancer. However, obese people seem to do better after treatment compared with people of normal weight. Researchers at Memorial Sloan Kettering Cancer Center in New York have discovered that the fat surrounding kidney tumours may play a key role in the effectiveness of […]

read more
Showing all 3 results